SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Herlin M) "

Sökning: WFRF:(Herlin M)

  • Resultat 1-10 av 50
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Ruperto, N., et al. (författare)
  • The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus : prospective validation of the definition of improvement
  • 2006
  • Ingår i: Arthritis and Rheumatism. - : Wiley. - 0004-3591 .- 1529-0131. ; 55:3, s. 355-363
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To use the Pediatric Rheumatology International Trials Organization (PRINTO) core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus (SLE).METHODS: Thirty-seven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of juvenile SLE patients, achieved consensus on 128 patient profiles as being clinically improved or not improved. Using the physicians' consensus ratings as the gold standard measure, the chi-square, sensitivity, specificity, false-positive and false-negative rates, area under the receiver operating characteristic curve, and kappa level of agreement for 597 candidate definitions of improvement were calculated. Only definitions with a kappa value greater than 0.7 were retained. The top definitions were selected based on the product of the content validity score multiplied by its kappa statistic.RESULTS: The definition of improvement with the highest final score was at least 50% improvement from baseline in any 2 of the 5 core set measures, with no more than 1 of the remaining worsening by more than 30%.CONCLUSION: PRINTO proposes a valid and reproducible definition of improvement that reflects well the consensus rating of experienced clinicians and that incorporates clinically meaningful change in core set measures in a composite end point for the evaluation of global response to therapy in patients with juvenile SLE. The definition is now proposed for use in juvenile SLE clinical trials and may help physicians to decide whether a child with SLE responded adequately to therapy.
  •  
4.
  • Stratmann, Svea, 1989-, et al. (författare)
  • Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children
  • 2023
  • Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 37:3, s. 550-559
  • Tidskriftsartikel (refereegranskat)abstract
    • Despite improvement of current treatment strategies and novel targeted drugs, relapse and treatment resistance largely determine the outcome for acute myeloid leukemia (AML) patients. To identify the underlying molecular characteristics, numerous studies have been aimed to decipher the genomic- and transcriptomic landscape of AML. Nevertheless, further molecular changes allowing malignant cells to escape treatment remain to be elucidated. Mass spectrometry is a powerful tool enabling detailed insights into proteomic changes that could explain AML relapse and resistance. Here, we investigated AML samples from 47 adult and 22 pediatric patients at serial time-points during disease progression using mass spectrometry-based in-depth proteomics. We show that the proteomic profile at relapse is enriched for mitochondrial ribosomal proteins and subunits of the respiratory chain complex, indicative of reprogrammed energy metabolism from diagnosis to relapse. Further, higher levels of granzymes and lower levels of the anti-inflammatory protein CR1/CD35 suggest an inflammatory signature promoting disease progression. Finally, through a proteogenomic approach, we detected novel peptides, which present a promising repertoire in the search for biomarkers and tumor-specific druggable targets. Altogether, this study highlights the importance of proteomic studies in holistic approaches to improve treatment and survival of AML patients.
  •  
5.
  • Berntson, Lillemor, 1957-, et al. (författare)
  • HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis
  • 2008
  • Ingår i: British Journal of Rheumatology. - 0263-7103 .- 1460-2172 .- 0315-162X .- 1499-2752. ; 35:10, s. 2055-2061
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: Juvenile idiopathic arthritis (JIA) is a heterogeneous condition with very few clinical and laboratory signs that can help predict the course and severity of the disease in the individual patient. The cell-surface antigen HLA-B27 is well known to be associated with spondyloarthropathies, reactive arthritis, and enthesitis. HLA-B27 plays an important role in the classification of JIA, since evidence of sacroiliitis most often evolves after years of arthritis in other joints. We investigated the associations of HLA-B27 and the clinical manifestations of JIA using a method as close to a population-based study as possible.METHODS: We studied an incidence-based cohort of 305 patients collected prospectively in 3 Nordic countries (Sweden, Norway, Denmark). Clinical and serological data of the first 3 years of the disease were collected.RESULTS: HLA-B27 was found to be positive in 25.5% of the patients, and we found a higher proportion of HLA-B27-positive boys with older age at disease onset (p=0.034). Regression analysis showed a correlation of 0.7 in the HLA-B27-positive boys, pointing to a higher risk of more joint involvement with older age at disease onset. By Fisher's exact test, involvement of small joints in the lower extremities was associated with HLA-B27 in boys (p=0.011), but not in girls (p=0.687). HLA-B27 was associated with inflammatory back pain in both sexes (p=0.041 in boys, p=0.042 in girls), but with enthesitis only in boys (p<0.001 in boys, p=0.708 in girls).CONCLUSION: HLA-B27 is of increasing importance with older age at disease onset in boys with JIA, predicting more active joints within the first 3 years of disease, and also involving small joints in the lower extremity to a greater degree than in HLA-B27-negative boys. During the first 3 years of disease the occurrence of HLA-B27 is associated with inflammatory back pain in both sexes, but with enthesitis only in boys. Our data present new challenges for the ILAR classification of JIA.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 50
Typ av publikation
tidskriftsartikel (38)
konferensbidrag (10)
annan publikation (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (39)
övrigt vetenskapligt/konstnärligt (10)
Författare/redaktör
Herlin, M (21)
Hakansson, H (19)
Viluksela, M (15)
Herlin, T. (11)
Nielsen, S (10)
Rygg, M (10)
visa fler...
Tuukkanen, J (10)
Fasth, Anders, 1945 (8)
Aalto, K (7)
Korkalainen, M (7)
Akesson, A. (6)
Zak, M (6)
Nordal, E (6)
Finnila, MAJ (6)
Peltoniemi, S. (6)
Andersson-Gäre, Boel (5)
Holmfeldt, Linda (5)
Esteban, J (5)
Jamsa, T (5)
Cavelier, Lucia (4)
Sundström, Christer (4)
Höglund, Martin (4)
Berntson, Lillemor, ... (4)
Hamscher, G (4)
Herlin, G (4)
Bowers, WJ (4)
Stern, N (4)
Elabbas, LE (4)
Miettinen, HM (4)
Zioupos, P (4)
Herlin, M. K. (4)
Skaftason, A (4)
Lahdenne, P (3)
Abrahamsson, Jonas, ... (3)
Palle, Josefine, 196 ... (3)
Zeller, B (3)
Herlin, Maria (3)
Jahnukainen, K (3)
Berntson, Lillemor (3)
Barber, X (3)
Rendel, F (3)
Risteli, J (3)
Berntson, L. (3)
Trossvik, C (3)
Finnila, M (3)
Eriksson, Anna, 1977 ... (3)
Aula, A (3)
van der Ven, LTM (3)
Rypdal, V. (3)
Tamm, K. P. (3)
visa färre...
Lärosäte
Karolinska Institutet (33)
Göteborgs universitet (14)
Uppsala universitet (14)
Jönköping University (5)
Umeå universitet (3)
Lunds universitet (3)
visa fler...
Malmö universitet (2)
Linköpings universitet (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (50)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (20)
Naturvetenskap (3)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy